Systemic Elimination of de novo Capsid Protein Synthesis from Replication-Competent AAV Contamination in the Liver
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The capsid protein synthesis in targeted tissues resulting from residual contaminating replication-competent adeno-associated virus particles (rcAAV) remains a concern for hazardous immune responses that shut down the factor IX expression in the hemophilia B clinical trial. To systematically reduce/eliminate the effects of potential contaminating rcAAV particles, we designed a novel adeno-associated virus (AAV) helper (pH22mir) with a microRNA binding cassette containing multiple copies of liver-specific (hsa-mir-122) and hematopoietic-specific (has-mir-142-3p) sequences to specifically control cap gene expression. In 293 cells, the rep and cap gene from pH22mir functioned similarly to that of conventional helper pH22. The vector yields and compositions from pH22mir and pH22 were indistinguishable. The performance of vector produced in this new system was comparable to that of similar vectors produced by conventional methods. In the human hepatic cell line, the capsid expression was reduced significantly from cap-mir cassette driven by a cytomegalovirus promoter. In the liver, 99.9% of capsid expression could be suppressed and no cap expression could be detected by western blot. In summary, we demonstrated a new concept in reducing de novo capsid synthesis in the targeted tissue. This strategy may not only help AAV vectors in controlling undesirable capsid gene expression, but can also be adopted for lentiviral or adenoviral vector production. Replication-competent adeno-associated viral particles (rcAAV) are an undesirable contaminant of vector preparations that may affect transgene expression or elicit a hazardous immune response. In this study, Yuan and colleagues have designed a recombinant AAV (rAAV) vector production system to tightly control AAV rep and capsid activity from rcAAV particles. According to the authors, this new method does not have any effects on rAAV yield or affect rAAV vector performance and is compatible with all current rAAV production systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 1×
“Adeno-associated virus (AAV) vector has shown greatpromise as a gene therapy vector in human clinical trials (Manno et al., 2006; Brantly et al., 2009; Maguire et al., 2009; Mendell et al., 2010).”
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655 · cited 2×
“Adeno-associated virus (AAV) vector has shown great promise as a gene therapy vector in human clinical trials (Manno et al., 2006; Brantly et al., 2009; Maguire et al., 2009; Mendell et al., 2010).”
Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327 · cited 2×
“Adeno-associated virus (AAV) vector has shown great promise as a gene therapy vector in human clinical trials (Manno et al., 2006; Brantly et al., 2009; Maguire et al., 2009; Mendell et al., 2010).”
Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192 · cited 5×
“…vector targeting the liver suggested that AAV capsid proteins, from either the capsid itself or rcAAV particles, may have caused the destructive immune response/ inflammation that eventually eliminated the therapeutic gene expression (Li et al., 2009a,b; Mays and Wilson, 2009; Pien et al., 2009).”
InfluentialTailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155 · cited 1×
“…not only affecting the safety of rAAV vectors, but also de- termining whether or not transgene expression can persist long-term (Manno et al., 2006; Murphy et al., 2008; Hauck et al., 2009; Li et al., 2009a; Mays and Wilson, 2009; Mays et al., 2009; Pien et al., 2009; Vandenberghe et al., 2009a,b).”
Hauck, B., Murphy, S. L., Smith, P. H., Qu, G., Liu, X., Zelenaia, O., Mingozzi, F., Sommer, J. M., High, K. A., & Wright, J. F. (2009) · Molecular Therapy · doi:10.1038/mt.2008.227 · Cited by 88 · cited 2×
“…not only affecting the safety of rAAV vectors, but also de- termining whether or not transgene expression can persist long-term (Manno et al., 2006; Murphy et al., 2008; Hauck et al., 2009; Li et al., 2009a; Mays and Wilson, 2009; Mays et al., 2009; Pien et al., 2009; Vandenberghe et al., 2009a,b).”
Self-citationCellular immune response to cryptic epitopes during therapeutic gene transfer
Li, C., Goudy, K., Hirsch, M., Asokan, A., Fan, Y., Alexander, J., Sun, J., Monahan, P., Seiber, D., Sidney, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902269106 · Cited by 79 · cited 3×
“…not only affecting the safety of rAAV vectors, but also de- termining whether or not transgene expression can persist long-term (Manno et al., 2006; Murphy et al., 2008; Hauck et al., 2009; Li et al., 2009a; Mays and Wilson, 2009; Mays et al., 2009; Pien et al., 2009; Vandenberghe et al., 2009a,b).”
Li, C., Hirsch, M., DiPrimio, N., Asokan, A., Goudy, K., Tisch, R., & Samulski, R. J. (2009) · Journal of Virology · doi:10.1128/jvi.00278-09 · Cited by 42 · cited 3×
“…not only affecting the safety of rAAV vectors, but also de- termining whether or not transgene expression can persist long-term (Manno et al., 2006; Murphy et al., 2008; Hauck et al., 2009; Li et al., 2009a; Mays and Wilson, 2009; Mays et al., 2009; Pien et al., 2009; Vandenberghe et al., 2009a,b).”
Identification of the murine AAVrh32.33 capsid-specific CD8+ T cell epitopes
Mays, L. E., & Wilson, J. M. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1402 · Cited by 13
Cited by
Wright, J. (2014) · Biomedicines · doi:10.3390/biomedicines2010080 · Cited by 219
“plasmids [56], incorporation of a microRNA binding cassette proximal to the AAV cap helper component [61] and sequestration of AAV helper rep and cap from vector genome DNA components in different sub-cellular compartments [62].”
BackgroundEnhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
Bartel, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00204 · Cited by 108
Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms
Robert, M., Chahal, P. S., Audy, A., Kamen, A., Gilbert, R., & Gaillet, B. (2017) · Biotechnology Journal · doi:10.1002/biot.201600193 · Cited by 89
Lecomte, E., Tournaire, B., Cogné, B., Dupont, J.-B., Lindenbaum, P., Martin-Fontaine, M., Broucque, F., Robin, C., Hebben, M., Merten, O.-W., et al. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.32 · Cited by 83
Schnödt, M., & Büning, H. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.188 · Cited by 77
Tanaka, T., Hanaoka, H., & Sakurai, S. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.08.002 · Cited by 27
Metadata
- Authors
- Lu, H., Qu, G., Yang, X., Xu, R., & Xiao, W.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2011-05
- Volume
- 22
- Issue
- 5
- Pages
- 625-632
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2067859851
- Cited by
- 14
- References
- 9
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.